Lilly Zyprexa IM Launch Planned For 2001; 2Q Sales Top $550 Mil.
Executive Summary
Lilly hopes to introduce an intramuscular formulation of the antipsychotic Zyprexa by mid-2001.
You may also be interested in...
Pfizer Adds Muscle To Geodon; IM Could Agitate Schizophrenia Market
Pfizer's intramuscular formulation of Geodon (ziprasidone) is indicated for "rapid control of agitation" in schizophrenic patients
Pfizer Adds Muscle To Geodon; IM Could Agitate Schizophrenia Market
Pfizer's intramuscular formulation of Geodon (ziprasidone) is indicated for "rapid control of agitation" in schizophrenic patients
Pfizer Ziprasidone Labeling Stops Short Of Second-Line Use; QT Effect Noted
Labeling for Pfizer's ziprasidone (Zeldox) recommends that doctors first consider prescribing antipsychotic agents associated with lower rates of QTc prolongation, but stops short of a second-line designation for the drug.